Lexeo Therapeutics (NASDAQ:LXEO) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Lexeo Therapeutics (NASDAQ:LXEO) from a hold rating to a strong sell rating in a research note published on Saturday morning.

Other research analysts have also issued reports about the company. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. JPMorgan Chase & Co. reduced their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. Finally, Weiss Ratings downgraded Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $18.75.

Lexeo Therapeutics Stock Down 2.4%

Shares of NASDAQ:LXEO opened at $4.84 on Friday. The firm has a fifty day moving average of $4.65 and a two-hundred day moving average of $5.63. The firm has a market capitalization of $397.12 million, a P/E ratio of -4.21 and a beta of 1.46. Lexeo Therapeutics has a 12-month low of $3.99 and a 12-month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.01). Equities research analysts expect that Lexeo Therapeutics will post -1.2 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Richard Nolan Townsend sold 25,947 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer owned 377,817 shares of the company’s stock, valued at approximately $1,692,620.16. This represents a 6.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the transaction, the insider directly owned 82,194 shares in the company, valued at $363,297.48. The trade was a 21.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 62,204 shares of company stock valued at $280,089. 2.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Lexeo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of LXEO. Legal & General Group Plc bought a new position in Lexeo Therapeutics in the 2nd quarter worth $32,000. Allworth Financial LP boosted its holdings in Lexeo Therapeutics by 1,002.9% during the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after acquiring an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after acquiring an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at about $37,000. Finally, California State Teachers Retirement System grew its position in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after purchasing an additional 2,148 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.